ADAM28

Across TCGA pan-cancer cohorts, ADAM28 mass-spec protein is linked to patient survival in 5 of 34 cancer types, making it a survival-associated ADAM28 data layer compared with 25 for mass-spec protein and 6 for mutation status.

The strongest signal is observed in pancreatic ductal adenocarcinoma (PDAC), where higher ADAM28 mass-spec protein is associated with better disease-free survival. In most high-consensus cancer types, elevated ADAM28 expression acts as an unfavorable survival marker, although some lineages such as PDAC and UCEC show a favorable association.

PDAC, LSCC, and UCEC are the cancer types where ADAM28 mass-spec protein most reproducibly stratifies survival.

mass-spec protein survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
PDAC	DFS	Median	III,IV	0.551	0.202	.007	6	view →
LSCC	DFS	Quartile	II,III,IV	0.497	0.830	.023	5	view →
UCEC	OS	Median	All	0.963	0.851	.020	4	view →
LUAD	OS	Median	III,IV	0.257	0.821	.024	3	view →
HNSC	OS	Median	All	0.939	0.803	.031	1	view →

Pink = unfavorable, green = favorable. Showing the 5 strongest of 5 lineages.

ADAM28–PDAC (DFS)

Open the PDAC breakdown →